triocean | Adobe Stock
The U.S. Food & Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages 1 through 3 years with a confirmed diagnosis of peanut allergy to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
Palforzia has been approved since January 2020 for initiation of treatment in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy with up-dosing and maintenance in individuals 4 years of age and older.
Those who take Palforzia must continue to avoid peanuts in their diets. A Risk Evaluation and Mitigation Strategy (REMS) is in place for Palforzia to mitigate the risk of anaphylaxis associated with Palforzia, which includes elements to assure safe use.
Latest from Quality Assurance & Food Safety
- FDA Releases Produce Regulatory Program Standards
- Invest in People or Risk the System: Darin Detwiler and Catalyst Food Leaders on Building Real Food Safety Culture
- USDA Proposes Increasing Poultry, Pork Line Speeds
- FDA Releases New Traceability Rule Guidance
- TraceGains and iFoodDS Extend Strategic Alliance
- bioMérieux Launches New Platform for Spoiler Risk Management
- SafetyChain Receives SOC 2 Type 2 Certification
- Puratos Acquires Pennsylvania-Based Vör Foods
